Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) insider Mark A. Goldsmith sold 30,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $35.05, for a total transaction of $1,051,500.00. Following the sale, the insider now owns 357,386 shares in the company, valued at approximately $12,526,379.30. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Revolution Medicines Stock Performance
Revolution Medicines stock opened at $32.09 on Friday. Revolution Medicines, Inc. has a fifty-two week low of $17.03 and a fifty-two week high of $35.50. The stock has a market cap of $3.50 billion, a PE ratio of -10.22 and a beta of 1.36. The firm’s 50-day simple moving average is $29.33 and its 200 day simple moving average is $25.85.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.10). Revolution Medicines had a negative return on equity of 36.46% and a negative net margin of 1,003.36%. The firm had revenue of $3.82 million for the quarter, compared to analysts’ expectations of $1.56 million. During the same quarter last year, the firm posted ($0.82) earnings per share. The firm’s revenue for the quarter was down 58.1% compared to the same quarter last year. As a group, analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. Needham & Company LLC lowered their target price on shares of Revolution Medicines from $35.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, August 9th. Oppenheimer raised their price target on shares of Revolution Medicines from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, August 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of Revolution Medicines in a report on Wednesday, August 2nd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $33.67.
About Revolution Medicines
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors.
- Five stocks we like better than Revolution Medicines
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- These 3 Wood Stocks are about to go on Discount
- Why Are Stock Sectors Important to Successful Investing?
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
- Investing in Agriculture 101: How to Invest in Agriculture
- 3 Stocks Awaiting Winter Winds of Opportunity
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.